ArticleGastroenterology2011
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.
Article in Gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01423643 (HCV/HIV Coinfection), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation.The Journal of infectious diseases · 2025Trial
- Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Risk of Hepatocellular Carcinoma or Hepatic Decompensation Associated With Steatotic Liver Disease in People With and Without HIV.Open forum infectious diseases · 2026Article
- Predictors of Liver Steatosis Progression Among People Living With HIV in Low- and Middle-Income Countries: A Multicentre Longitudinal Study.Journal of the International AIDS Society · 2026Article
- Article
- A Step Closer to the "Fourth 90": A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?The Journal of infectious diseases · 2020Review
- HIV and the liver.Topics in antiviral medicine · 2019Article
- Fatty liver disease in persons with HIV infection.Topics in antiviral medicine · 2019Article
- Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.Medicine · 2018Observational
- Human immunodeficiency virus and liver disease: A comprehensive update.Hepatology communications · 2017Article
- Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.World journal of gastroenterology · 2016Review
- Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.Toxicology in vitro : an international journal published in association with BIBRA · 2016Article
- Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis.World journal of hepatology · 2016Article
- Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.Current atherosclerosis reports · 2015Review
- Liver steatosis in hepatitis C patients.World journal of hepatology · 2015Review
- Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients.Open forum infectious diseases · 2015Article
- Hepatitis C virus infection in the human immunodeficiency virus infected patient.World journal of gastroenterology · 2014Review
- Serum sclerostin in hepatitis C virus infected patients.Journal of bone metabolism · 2014Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsHepatic steatosis is a common histologic finding in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), although little is known about its natural history. We prospectively examined the natural history of steatosis in patients coinfected with HIV and HCV who attended an urban HIV clinic.
methodsThe study cohort consisted of 222 coinfected patients (87% black, 94% with HCV genotype 1 infection) who had at least 2 liver biopsies performed between 1993 and 2008. Biopsy specimens were scored by a single pathologist; samples were classified as having trivial (<5% of hepatocytes affected) or significant (>5%) levels of fat (steatosis). We characterized progression to significant levels of fat among patients whose first biopsy samples had no or trivial levels of fat, and regression among those with significant fat, using logistic regression.
resultsInitial biopsy specimens from most patients (88%) had no or trivial amounts of fat. Among second biopsy samples, 74% had no or trivial fat and 13% had significant amounts of fat. The strongest risk factors for progression of steatosis were alcohol abuse and overweight/obesity; cumulative exposure to antiretroviral therapy between biopsies and high counts of CD4(+) T cells were associated with reduced progression of steatosis. Among the 28 patients whose initial biopsy specimen had significant fat levels, most (75%) regressed.
conclusionsAntiretroviral therapy and high counts of CD4(+) T cells are associated with reduced progression of steatosis in patients coinfected with HIV and HCV. Efforts to diagnose and prevent steatosis should focus on persons with a high body mass index and excessive alcohol intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.